慢性阻塞性肺疾病全球倡议2019:慢性阻塞性肺疾病诊断、治疗与预防全球策略解读  

Interpretation of the Global Strategy for the Diagnosis,Management,and Prevention of COPD 2019 by GOLD

作　　者：王晓娟[1,2] 方向阳[1] WANG Xiaojuan;FANG Xiangyang(General Department,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China;Beijing Institute of Respiratory Diseases,Beijing 100020,China)

机构地区：[1]首都医科大学附属北京朝阳医院综合科,北京市100020 [2]北京呼吸疾病研究所,北京市100020

出　　处：《中国全科医学》2019年第18期2141-2149,共9页Chinese General Practice

基　　金：北京市属医院科研培育计划项目(PX2018014)

摘　　要：慢性阻塞性肺疾病全球倡议(GOLD)2019于2018-11-07发布,更新涉及慢性阻塞性肺疾病(COPD)的危险因素、诊断、预防、稳定期及急性加重期的管理、药物治疗及非药物治疗等诸多方面。重点在于对稳定期COPD患者的药物治疗路径从“初始治疗”“管理循环”和“随访调整治疗”三个方面建立管理循环,并首次纳入血嗜酸粒细胞计数作为指导吸入糖皮质激素临床应用的生物标志物。本文旨在对GOLD 2019的重要更新内容进行介绍。The Global Initiative for Chronic Obstructive Lung Disease (GOLD)(2019 Report) was released on November 7,2018.The updates of the report involve the risk factors,diagnosis,prevention of COPD,management of stable COPD,management of exacerbations,and pharmacological and non-pharmacological treatments.The report focuses on the initiation pharmacological treatment,management cycly and follow-up pharmacological management of stable COPD according to the individualized assessment of symptoms and exacerbations.It also emphasizes the use of peripheral blood eosinophil counts as a biomarker to guide the use of inhaled corticosteroid therapy for exacerbation prevention.Here is an interpretation of the report.

关 键 词：肺疾病 慢性阻塞性 初始治疗 管理循环 随访调整治疗 血嗜酸粒细胞计数 糖皮质激素类 

分 类 号：R563.9[医药卫生—呼吸系统]